Telbivudine: A new treatment for chronic hepatitis B

Table 2 Efficacy at 1 yr against virological suppression at 24 wk in HBeAg positive and negative individuals in the Globe study

	Virological suppression at wk 24 (%)
	< 300copies/mL	300-1000copies/mL	> 1000-10 000copies/mL	> 10 000copies/mL
HBeAg positive patients (wk 52)
HBV DNA (< 300 copies/mL)	90	70	30	5
ALT normalization	90	89	80	54
Viral breakthrough	1	3	8	11
HBeAg negative patients (wk 52)
HBV DNA (< 300 copies/mL)	93	66	38	10
ALT normalization	83	74	63	36
Viral breakthrough	0	9	18	32